Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW trial of RAY121 in classical complement pathway-mediated immunological diseases
NL-OMON60032Phase 1Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RAY121 in antiphospholipid syndrome (APS), Bullous Pemphigoid (BP), Behçet's disease (BD) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Started Nov 2024; status: recruiting.
02
Drugs
RAY121
03
Conditions
antiphospholipid syndrome (APS)Bullous Pemphigoid (BP)Behçet's disease (BD)immune-mediated necrotizing myopathy (IMNM)dermatomyositis (DM)
Beyond the preview
Go deeper on NL-OMON60032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60032.